An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase i clinical trial

npj Vaccines

Volumn 2, Issue 1, 2017, Pages

  DeZure, Adam D ^a   Coates, Emily E ^a   Hu, Zonghui ^a   Yamshchikov, Galina V ^a   Zephir, Kathryn L ^a   Enama, Mary E ^a   Plummer, Sarah H ^a   Gordon, Ingelise J ^a   Kaltovich, Florence ^a   Andrews, Sarah ^a   McDermott, Adrian ^a   Crank, Michelle C ^a   Koup, Richard A ^a   Schwartz, Richard M ^a,c   Bailer, Robert T ^a   Sun, Xiangjie ^b   Mascola, John R ^a   Tumpey, Terrence M ^b   Graham, Barney S ^a   Ledgerwood, Julie E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c SYNLOGIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85041507182     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/s41541-017-0016-6     Document Type: Article

References (43)

1. Gao, R. et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Eng. J. Med. 368, 1888-1897 (2013).
2. Watanabe, T., Watanabe, S., Maher, E. A., Neumann, G. & Kawaoka, Y. Pandemic potential of avian influenza A (H7N9) viruses. Trends Microbiol. 22, 623-631 (2014).
3. Li, Q. et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N. Eng. J. Med. 370, 520-532 (2014).
4. Uyeki, T. M. & Cox, N. J. Global concerns regarding novel influenza A (H7N9) virus infections. N. Eng. J. Med. 368, 1862-1864 (2013).
5. Farooqui, A. et al. Probable hospital cluster of H7N9 influenza infection. N. Eng. J. Med. 374, 596-598 (2016).
6. Belshe, R. B. The origins of pandemic influenza - lessons from the 1918 virus. N. Eng. J. Med. 353, 2209-2211 (2005).
7. Taubenberger, J. K. et al. Characterization of the 1918 influenza virus polymerase genes. Nature 437, 889-893 (2005).
8. Watanabe, T. et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 501, 551-555 (2013).
9. Zhu, H. et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 341, 183-186 (2013).
10. Belser, J. A. et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 501, 556-559 (2013).
11. Chan, M. C. et al. Tropism and innate host responses of a novel avian influenza A H7N9 virus: an analysis of ex-vivo and in-vitro cultures of the human respiratory tract. Lancet Respir. Med. 1, 534-542 (2013).
12. Cox, R. J. Correlates of protection to influenza virus, where do we go from here? Hum. Vaccin. Immunother. 9, 405-408 (2013).
13. Couch, R. B., Patel, S. M., Wade-Bowers, C. L. & Nino, D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS ONE 7, e49704 (2012).
14. Blanchfield, K. et al. Recombinant influenza H7 hemagglutinins induce lower neutralizing antibody titers in mice than do seasonal hemagglutinins. Influenza Other Respir. Viruses 8, 628-635 (2014).
15. Cox, R. J. et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27, 1889-1897 (2009).
16. Babu, T. M. et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 32, 6798-6804 (2014).
17. Sobhanie, M. et al. Evaluation of the safety and immunogenicity of a candidate pandemic live attenuated influenza vaccine (pLAIV) against influenza A(H7N9). J. Infect. Dis. 213, 922-929 (2016).
18. Graham, B. S. et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194, 1650-1660 (2006).
19. Martin, J. E. et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26, 6338-6343 (2008).
20. Martin, J. E. et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196, 1732-1740, doi: 10.1086/523650 (2007).
21. Martin, J. E. et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin. Vaccine. Immunol. 13, 1267-1277 (2006).
22. Ledgerwood, J. E. et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11, 916-924 (2011).
23. Khurana, S. et al. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J. Infect. Dis. 208, 413-417 (2013).
24. Ledgerwood, J. E. et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J. Infect. Dis. 208, 418-422 (2013).
25. Mulligan, M. J. et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 312, 1409-1419 (2014).
26. Guo, L. et al. Human antibody responses to avian influenza A(H7N9) virus, 2013. Emerg. Infect. Dis. 20, 192-200 (2014).
27. Wang, S. et al. Heterologous HA DNA vaccine prime - inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26, 3626-3633 (2008).
28. Ledgerwood, J. E. et al. Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin. Vaccine Immunol. 19, 1792-1797 (2012).
29. Ledgerwood, J. E. et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J. Infect. Dis. 203, 1396-1404 (2011).
30. Wei, C. J. et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064 (2010).
31. Yang, S. et al. Avian-origin influenza A(H7N9) infection in influenza A(H7N9)-affected areas of China: a serological study. J. Infect. Dis. 209, 265-269 (2014).
32. Zhang, A. et al. Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013. Euro. Surveill. 18, 20657 (2013).
33. Goodwin, K., Viboud, C. & Simonsen, L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24, 1159-1169 (2006).
34. Bart, S. A. et al. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci. Transl. Med. 6, 234ra255 (2014).
35. Fries, L. F., Smith, G. E. & Glenn, G. M. A recombinant virus like particle influenza A (H7N9) vaccine. N. Eng. J. Med. 369, 2564-2566 (2013).
36. Jackson, L. A. et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: A randomized clinical trial. JAMA 314, 237-246 (2015).
37. Graham, B. S. et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8 + T-cell responses after rAd5 boost in a randomized clinical trial. PLoS ONE 8, e59340 (2013).
38. Crank, M. C. et al. Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS ONE 10, e0123969 (2015).
39. Ledgerwood, J. E. et al. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent Influenza inactivated vaccine (IIV3) boost. Contemp. Clin. Trials. doi: 10.1016/j.cct.2015.08.006 (2015).
40. Ledgerwood, J. E. et al. DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. PLoS ONE 10, e0125914 (2015).
41. Yang, Z. Y. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561-564 (2004).
42. Yang, Z. Y. et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 78, 5642-5650 (2004).
43. Barouch, D. H. et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79, 8828-8834 (2005).